亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Improving HSC engraftment

详细技术说明
Hematopoietic Stem Cell (HSC) transplantation is the only curative therapy for many hematologic diseases, as well as a critical life-saving therapy following high dose chemotherapy for many non-hemato
*Abstract
Hematopoietic Stem Cell (HSC) transplantation is the only curative therapy for many hematologic diseases, as well as a critical life-saving therapy following high dose chemotherapy for many non-hematopoietic cancers. Researchers at St. Jude Children's Research Hospital have developed a way to enhance HSC transplantation by treating pre-graft cells with silencing constructs for reducing expression of GASP (G-protein coupled receptor Associated Sorting Proteins) family genes, either permanently or transiently to improve the ability of these cells to replenish the hematopoietic system of host organisms. Further, the use of GASP gene silenced umbilical cord blood-derived cells is contemplated for transplantation into HLA mismatched (allogeneic) hosts.Benefits to this new method include:•Accelerating reconstitution of the hematopoietic compartment to narrow the window during which patients are most susceptible to infection.•Reducing pre-transplant conditioning to lower the risk of common long-term term side effects (secondary malignancies, adaptive immune dysfunction, growth failure, gonadal dysfunction, thyroid dysfunction).•Improving the efficiency of umbilical cord blood (UCB)* and other HSC transplantation. (*UCB transplants tolerate greater HLA mismatch.)Overcoming limitations on the amount of UCB cells required for HSC transplantation in adults.
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备